2024
Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML
Shimony S, Bewersdorf J, Shallis R, Liu Y, Schaefer E, Zeidan A, Goldberg A, Stein E, Marcucci G, Lindsley R, Chen E, Ramos Perez J, Stein A, DeAngelo D, Neuberg D, Stone R, Ball B, Stahl M. Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML. Leukemia 2024, 38: 762-768. PMID: 38378841, DOI: 10.1038/s41375-024-02175-0.Peer-Reviewed Original ResearchAssociated with improved OSHypomethylating agentsCPX-351Overall survivalSplicing factor mutationsCo-mutationsAllogeneic hematopoietic stem cell transplantationAssociated with better OSAssociated with worse OSSecondary acute myeloid leukemiaHematopoietic stem cell transplantationMedian overall survivalStem cell transplantationPatients aged >Acute myeloid leukemiaTreated with daunorubicinLiposomal daunorubicinMonosomal karyotypeNRAS/KRAS mutationsImproved OSSecondary AMLMyeloid diseasesMyeloid neoplasmsAML patientsAML treatment
2022
Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic
Bewersdorf J, Abdel-Wahab O. Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic. Genes & Development 2022, 36: 259-277. PMID: 35318270, PMCID: PMC8973851, DOI: 10.1101/gad.349368.122.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMyeloid leukemiaAnti-Tim-3 antibodiesPathogenesis of acute myeloid leukemiaTargeting of acute myeloid leukemiaMolecular targeted approachesUnmet medical needAnti-CD47IDH1/2 inhibitorsHematologic malignanciesSplicing factor mutationsCellular therapyPreclinical meansImmune targetsTET2</i>FDA approvalTrispecific antibodyMenin inhibitionMedical needLeukemiaAntibodiesIDH1/2MalignancyTherapyPatients